Minnesota Partnership Researchers Uncover Cancer Drug Prospects
Clues to possible drugs for two rare cancers through research involving baker’s yeast and a library of chemical compounds.
Gamechanger: Gunda Georg
Gunda Georg is an esteemed researcher and professor who has made a tremendous impact in the field of synthetic medicinal chemistry.
Gunda Georg Inducted into the Academy for Excellence in Health Research
The Academy for Excellence in Health Research is the highest recognition of excellence in research by Academic Health Center faculty
Welcome to the Institute for Therapeutics Discovery & Development
ITDD creates opportunities for drug discovery and early pre-clinical drug development through collaborations between various schools, colleges and research centers, as well as industrial throughout Minnesota and nationwide.
Hormone-Free Birth Control Research Advances
Researchers will investigate pharmaceutical alternatives to existing hormone-based birth control under a new $8.3M NIH contract.
The Journal of Medicinal Chemistry
The Journal of Medicinal Chemistry publishes studies that contribute to an understanding of the relationship between molecular structure and biological activity or mode of action.
ITDD faculty involved with NIPTE/NIH Therapeutics For Rare And Neglected Diseases (TRND) Program
In July 2012, the National Institute for Pharmaceutical Technology and Education (NIPTE) signed a contract with SAIC-Frederick, Inc.
Grant Received From Minnesota Partnership for Biotechnology and Medical Genomics
Michael Walters, ITDD Lead and Probe Discovery Core Director, received an $800,000 grant from the Minnesota Partnership for Biotechnology and Medical Genomics for the project "Development of SaferRead more...
Dr. Michael Walters coauthors commentary published in Nature
Chemistry: Chemical Con Artists Foil Drug Discovery, a commentary co-authored byRead more...
Director, Institute for Therapeutics Discovery and Development
Professor and Department Head, Department of Medicinal Chemistry; Robert Vince Endowed Chair; McKnight Presidential Chair
Dr. Georg’s expertise includes synthetic medicinal agents, natural products chemistry, and the development of new synthetic methods. She is the co-inventor of Lusedra® and several other drug candidates, as well as the co-founder of ProQuest Pharmaceuticals, Inc. (now a part of Eisai Pharmaceuticals). The ITDD core directors have extensive academic and industrial drug discovery and development expertise. The group uses advanced research and development techniques, including high through-put screening, structure-based drug design, computer modeling, chem- and bioinformatics methods, and animal models to translate basic biomedical discoveries towards new approaches for prevention, treatment, and cures